Gilead Sciences Inc. (GILD) has taken the proactive step of voluntarily recalling one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial. This decision comes after the company discovered the presence of glass particles in the vials. The discovery was triggered by a customer complaint, leading to an investigation that confirmed the foreign material in the product.
The affected product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is ensuring swift communication by notifying distributors and customers through UPS next-day air mail. Pharmacies are instructed to immediately cease using the affected lot and return any remaining vials.
Gilead is committed to patient and healthcare provider safety and is taking necessary measures to facilitate the recall process efficiently. The administration of a contaminated injectable could pose significant health risks, potentially leading to local irritation or swelling. More concerning is the possibility of glass particles traveling through the bloodstream, obstructing blood vessels in vital organs. This could result in severe complications such as strokes or even death. While Gilead has reported no adverse events associated with this recall to date, the company prioritizes preventative measures to ensure patient well-being.
Veklury is an essential treatment for COVID-19, designed for use in both adults and pediatric patients. It is particularly crucial for those who are hospitalized or non-hospitalized but at high risk of developing severe COVID-19. Due to the potential for severe reactions, including anaphylaxis, its use is restricted to healthcare settings equipped to manage such emergencies.
It is important to note that this is not the first recall for Gilead’s COVID-19 treatment. In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir due to the same issue – the presence of glass particulates.
Despite the recall, Veklury remains an essential treatment option for COVID-19. However, the recent recall highlights the importance of rigorous quality control measures in the pharmaceutical industry to ensure the safety of patients. It also underscores the need for ongoing vigilance and proactive responses to potential issues that could compromise patient health.
In the second quarter of 2024, Veklury sales decreased 16% year over year to $214 million, primarily due to lower rates of COVID-19-related hospitalizations. This decrease in sales reflects the overall decline in COVID-19 cases and hospitalizations.
As of Monday, GILD stock is down 0.05% at $83.90.
